Diagnostic value of NIPT assay for fetal aneuploidy screening in pregnant women with moderate risk of trisomy in first stage screening

Document Type : Original Article

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, Kowsar Clinical Development and Research Unit, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

2 Gynecologist, Kowsar Clinical Development and Research Unit, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

3 Medical Geneticist, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

4 Assistant professor, Department of Community Medicine, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

Abstract

Introduction: Aneuploidies are of the most important fetal abnormalities. Diagnostic value and efficacy of NIPT assay in the groups with abnormal results for first trimester combined screening test is not well defined. Therefore, this study was performed aimed to survey the sensitivity and specificity of NIPT for aneuploidies diagnosis in women with moderate risk for trisomy at first trimester combined screening test.
Methods: This prospective cohort study was performed in 2017-2018 on 447 women with singleton pregnancy and gestational age of 11 to 13 weeks and 6 days who had moderate risk for trisomy. NIPT analysis was done in all women with moderate risk (1/250 to 1/1500) and was compared with the results from karyotype and phenotype analysis in neonates. NIPT diagnostic accuracy for chromosomal abnormalities was calculated. Data were analyzed using SPSS statistical software (version 22).
Results: Two cases with trisomy 21 (0.06%) and one case with trisomy 18 (0.03%) were diagnosed. These three cases were confirmed with amniocentesis and the pregnancy was ended. The neonates' analysis showed normal phenotype results in all of them and NIPT diagnostic accuracy for trisomy 21 and 18 was calculated 100%.
Conclusion: In addition to maintain combined screening test benefits, using NIPT is accompanied by high diagnostic accuracy for fetal chromosomal abnormalities assessment.

Keywords

References

  1. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams Obstetrics. 24nd New York: McGraw-Hill Education; 2015.
  2. Reddy UM, Page GP, Saade GR, Silver RM, Thorsten VR, Parker CB, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. New England journal of medicine 2012; 367(23):2185-93.
  3. Stevenson DA, Carey JC. Contribution of malformations and genetic disorders to mortality in a children's hospital. American Journal of Medical Genetics Part a 2004; 126(4):393-7.
  4. Wou K, Hyun Y, Chitayat D, Vlasschaert M, Chong K, Wasim S, et al. Analysis of tissue from products of conception and perinatal losses using QF-PCR and microarray: A three-year retrospective study resulting in an efficient protocol. European journal of medical genetics 2016; 59(8):417-24.
  5. Sekizawa A, Samura O, Zhen D, Falco V, Farina A, Bianchi DW. Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. Prenatal diagnosis 2000; 20(11):886-9.
  6. Miltoft CB, Rode L, Ekelund CK, Sundberg K, Kjaergaard S, Zingenberg H, et al. Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical setting. Ultrasound in Obstetrics & Gynecology 2018; 51(4):470-9.
  7. Carrara J, Vivanti A, Jani JC, Demain A, Costa JM, Benachi A. Usefulness and reliability of cell free fetal DNA screening for main trisomies in case of atypical profile on first trimester maternal serum screening. Journal of translational medicine 2019; 17(1):1-8.
  8. Cotarelo-Pérez C, Oancea-Ionescu R, Asenjo-de-la-Fuente E, Ortega-de-Heredia D, Soler-Ruiz P, Coronado-Martín P, et al. A contingent model for cell-free DNA testing to detect fetal aneuploidy after first trimester combined screening. European journal of obstetrics & gynecology and reproductive biology: X 2019; 1:100002.
  9. Dukhovny S, Zera C, Little SE, McElrath T, Wilkins-Haug L. Eliminating first trimester markers: will replacing PAPP-A and β hCG miss women at risk for small for gestational age?. The Journal of Maternal-Fetal & Neonatal Medicine 2014; 27(17):1761-4.
  10. Baer RJ, Flessel MC, Jelliffe-Pawlowski LL, Goldman S, Hudgins L, Hull AD, et al. Detection rates for aneuploidy by first-trimester and sequential screening. Obstetrics & Gynecology 2015; 126(4):753-9.
  11. Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstetrics & Gynecology 2014; 124(5):979-86.
  12. Capriglione S, Latella S, De Felice G, Filippini M, Ettore C, Ettore G, et al. First trimester screening for aneuploidy: may combined test and fetal DNA work together?. The Journal of Maternal-Fetal & Neonatal Medicine 2020: 1-5.
  13. Amiri FN, Basirat Z, Omidvar S, Sharbatdaran M, Tilaki KH, Pouramir M. Comparison of the serum iron, ferritin levels and total iron-binding capacity between pregnant women with and without gestational diabetes. Journal of natural science, biology, and medicine 2013; 4(2):302.
  14. Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. The American journal of medicine 2009; 122(10):890-5.
  15. Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Obstetrics & Gynecology 2000; 95(1):24-8.
  16. Buchbinder A, Sibai BM, Caritis S, MacPherson C, Hauth J, Lindheimer MD, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. American journal of obstetrics and gynecology 2002; 186(1):66-71.
  17. Thureen PJ, Anderson MS, Hay WW. The small-for-gestational age infant. NeoReviews 2001; 2(6):e139-49.
  18. Martin JA, Kung HC, Mathews TJ, Hoyert DL, Strobino DM, Guyer B, et al. Annual summary of vital statistics: 2006. Pediatrics 2008; 121(4):788-801.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 25, Issue 4
June 2022
Pages 1-8

Files

Share

How to cite

Statistics